MMSI Merit Medical Systems Inc.

Merit Medical Launches the basixALPHA™ Inflation Device

Merit Medical Launches the basixALPHA™ Inflation Device

Ergonomic device provides fast inflation to streamline angioplasty procedures

SOUTH JORDAN, Utah, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced U.S. commercial release of the basixALPHA™ Inflation Device.

The basixALPHA is the latest addition to the Merit inflation device portfolio. Products include analog and digital devices with low- and high-pressure capacity for inflation, deflation, and measurement of pressures in angioplasty balloons. Merit’s commitment to excellence in inflation device technology has resulted in decades of industry leadership. More than 10 million procedures have been completed using Merit inflation devices worldwide.

The new ergonomic device is designed for one-handed preparation and fast inflation with minimal exertion to streamline angioplasty procedures. Angioplasty, a type of percutaneous coronary intervention (PCI), is used to open narrowed or blocked arteries. Opening blocked arteries facilitates blood flow to the heart, minimizing damage. More than 1.2 million coronary angioplasty procedures are performed each year within the US.1

“As a leader in inflation device technology, Merit understands that inflation devices serve as staples in the cath lab,” said Fred P. Lampropoulos, Merit Medical’s Chairman and CEO. “To provide physicians with an improved device, we listened to their feedback and innovated the basixALPHA—a technology that delivers fast inflation when needed most. It fits well within our robust portfolio of inventive yet reliable inflation device technologies, helping to improve the physician experience and patient outcomes around the globe.”

1. Medical News Today. 2019. “What to Know About Angioplasty.”

ABOUT MERIT MEDICAL Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling in excess of 600 individuals. Merit employs approximately 6,500 people worldwide.

TRADEMARKS Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc. and its subsidiaries in the United States and other jurisdictions.

CONTACTS

PR/Media Inquiries 

Sarah Comstock 

Merit Medical 

|

INVESTOR INQUIRIES 

Mike Piccinino, CFA, IRC 

Westwicke - ICR 

|



EN
28/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Merit Medical Systems Inc.

 PRESS RELEASE

Merit Medical Reports Fourth Quarter and Full Year 2025 Results and Is...

Merit Medical Reports Fourth Quarter and Full Year 2025 Results and Issues Fiscal Year 2026 Guidance Fourth Quarter Highlights† Reported revenue of $393.9 million, up 11%Constant currency revenue* and constant currency revenue, organic* up 10% and up 7%, respectivelyGAAP operating margin of 13.8%, compared to 10.3% in prior year periodNon-GAAP operating margin* of 21.0%, compared to 19.6% in prior year periodGAAP EPS $0.63, up 37%Non-GAAP EPS* $1.04, up 12%Free cash flow* generation of $74.0 million, up 13% Fiscal Year 2025 Highlights† Reported revenue of $1.516 billion, up 12%Constant c...

 PRESS RELEASE

Merit Medical Appoints F. Ann Millner as Chair of the Board and Announ...

Merit Medical Appoints F. Ann Millner as Chair of the Board and Announces Projected Preliminary Unaudited Revenue Results for the Fourth Quarter of 2025 SOUTH JORDAN, Utah, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced that its Board of Directors unanimously appointed F. Ann Millner, Ed.D., formerly Merit’s Lead Independent Director, as Chair of the Board effective January 5, 2026. Dr. Millner has served as a director of Merit since 2015 and as the Lead Independent Director since July 2021. She prev...

 PRESS RELEASE

Merit Medical to Participate at the J.P. Morgan Healthcare Conference

Merit Medical to Participate at the J.P. Morgan Healthcare Conference SOUTH JORDAN, Utah, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced that management will participate in the 44th Annual J.P. Morgan Healthcare Conference, which is being held at The Westin St. Francis Hotel in San Francisco, California, January 12-15, 2026. To learn more, visit  Martha G. Aronson, President and Chief Executive Officer, and Raul Parra, Chief Financial Officer, will present a company overview and update on Tuesday, Ja...

Merit Medical Systems Inc: 1 director

A director at Merit Medical Systems Inc sold 10,000 shares at 88.038USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

 PRESS RELEASE

Merit Medical Provides Update on U.S. Reimbursement and Commercial Str...

Merit Medical Provides Update on U.S. Reimbursement and Commercial Strategies for WRAPSODY® Cell-Impermeable Endoprosthesis SOUTH JORDAN, Utah, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that the U.S. Centers for Medicare & Medicaid Services (“CMS”) has notified Merit that its application for Transitional Pass-Through (“TPT”) incremental payment for WRAPSODY® Cell-Impermeable Endoprosthesis (“CIE”) procedures in the outpatient and ambulatory surgery center (“ASC”) settings requires further conside...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch